The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval is supported by data from three pivotal clinical trials
Subscribe To Our Newsletter & Stay Updated
